Evidence map›Paper›PMID 39994739›Full record

ArticleGenome medicine2025

The landscape of Helicobacter pylori-mediated DNA breaks links bacterial genotoxicity to its oncogenic potential.

Hadas Sibony-Benyamini, Rose Jbara, Tania Shubash Napso, Layan Abu-Rahmoun, Daniel Vizenblit, Michal Easton-Mor, Shira Perez, Alexander Brandis, Tamar Leshem, Avi Peretz and 1 more

Abstract read
In one paragraph

Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. EradicatingBioactive materials · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Pathogenicity ofWorld journal of clinical oncology · 2025
    Review
  7. Review
  8. Review
  9. Vaccines · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hadas Sibony-BenyaminiAzrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Zefat, Israel.
Rose Jbara *Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Zefat, Israel.
Tania Shubash Napso *Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Zefat, Israel.
Layan Abu-Rahmoun *Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Zefat, Israel.
Daniel VizenblitAzrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Zefat, Israel.
Michal Easton-MorAzrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Zefat, Israel.
Shira PerezAzrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Zefat, Israel.
Alexander BrandisLife Sciences Core Facilities, Weizmann Institute, Rehovot, Israel.
Tamar LeshemBaruch Padeh Medical Center, Poriya, Israel.
Avi PeretzAzrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Zefat, Israel.
Yaakov MamanAzrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Zefat, Israel. yaakov.maman@biu.ac.il.ORCID 0000-0003-0005-1847

Funding

Israel Cancer Association 20220096Israel Cancer Research Fund 23-201-RCDAIsrael Science Foundation 1920/20The Goldberg Family Foundation 246043
6 · The paper itself

Abstract

backgroundHelicobacter pylori (H. pylori) infection is a significant risk factor for gastric cancer (GC) development. A growing body of evidence suggests a causal link between infection with H. pylori and increased DNA breakage in the host cells. While several mechanisms have been proposed for this damage, their relative impact on the overall bacterial genotoxicity is unknown. Moreover, the link between the formation of DNA damage following infection and the emergence of cancerous structural variants (SV) in the genome of infected cells remained unexplored.

methodsWe constructed a high-resolution map of genomic H. pylori-induced recurrent break sites using the END-seq method on AGS human gastric cells before and after infection. We next applied END-seq to cycling and arrested cells to identify the role of DNA replication on break formation. Recurrent H. pylori-mediated break sites were further characterized by analyzing published RNA-seq, DRIP-seq, and GRO-seq data at these sites. γH2AX staining and comet assay were used for DNA breakage quantification. Liquid chromatography-mass spectrometry (LC-MS) assay was used to quantify cellular concentrations of dNTPs.

resultsOur data indicated that sites of recurrent H. pylori-mediated DNA breaks are ubiquitous across cell types, localized at replication-related fragile sites, and their breakage is dependent on replication. Consistent with that, we found that H. pylori inflicts nucleotide depletion, and that rescuing the cellular nucleotide pool largely reduced H. pylori-induced DNA breaks. Intriguingly, we found that this genotoxic mechanism operates independently of H. pylori cag pathogenicity island (CagPAI) that encodes for the bacterial type 4 secretion system (T4SS), and its virulence factor, CagA, which was previously implicated in increasing DNA damage by downregulating the DNA damage response. Finally, we show that sites of recurrent H. pylori-mediated breaks coincide with chromosomal deletions observed in patients with intestinal-type GC and that this link potentially elucidates the persistent transcriptional alterations observed in cancer driver genes.

conclusionsOur findings indicate that dNTP depletion by H. pylori is a key component of its genotoxicity and suggest a link between H. pylori genotoxicity and its oncogenic potential.

Indexed as

DNA BreaksHelicobacter InfectionsHelicobacter pyloriCell Line, TumorDNA DamageDNA ReplicationHumansStomach NeoplasmsdNTP depletionGastric cancerGenome-instabilityHelicobacter pyloriReplication stressRRM2

Identifiers

PMID39994739
PMCPMC11853333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.